Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19034276 | 1.00 | LMNA (0.45) | LMNASMN1; SMN2GLP1RMAPTBCHE | |
| SCHEMBL23080632 | 0.94 | GLP1R (0.45) | LMNASMN1; SMN2GLP1RMAPTBCHE | |
| SCHEMBL25544093 | 0.91 | GLP1R (0.42) | LMNASMN1; SMN2GLP1RMAPTBCHE | |
| SCHEMBL23080633 | 0.91 | GLP1R (0.42) | LMNASMN1; SMN2GLP1RMAPTBCHE | |
| SCHEMBL31631358 | 0.91 | GLP1R (0.53) | GLP1RBCHEACHEKLK7KLK5 | |
| SCHEMBL20567680 | 0.91 | GLP1R (0.43) | LMNASMN1; SMN2GLP1RMAPTBCHE | |
| SCHEMBL20567681 | 0.91 | GLP1R (0.43) | LMNASMN1; SMN2GLP1RMAPTBCHE | |
| SCHEMBL3072460 | 0.88 | KMT2A (0.45) | LMNASMN1; SMN2GLP1RMAPTBCHE | |
| SCHEMBL1509841 | 0.88 | KMT2A (0.45) | LMNASMN1; SMN2GLP1RMAPTBCHE | |
| SCHEMBL23080735 | 0.87 | GLP1R (0.40) | GLP1RBCHEACHESIRT2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12447211-B2 | Therapeutic derivatives of interleukin-22 | CYTOKI PHARMA APS (DK) | 2025-10-21 | — | — | US | disclosed |
| US-12226487-B2 | Therapeutic derivatives of interleukin-22 | CYTOKI PHARMA APS (DK) | 2025-02-18 | — | — | US | disclosed |
| US-20240279297-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | CYTOKI PHARMA APS (DK) | 2024-08-22 | — | — | US | disclosed |
| US-20240252649-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | CYTOKI PHARMA APS (DK) | 2024-08-01 | — | — | US | disclosed |
| WO-2024133936-A2 | DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES | CYTOKI PHARMA APS (DK) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389138-A1 | DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES | Cytoki Pharma ApS (DK) | 2024-06-26 | — | — | EP | disclosed |
| US-20240108731-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | CYTOKI PHARMA APS (DK) | 2024-04-04 | — | — | US | disclosed |
| EP-4337681-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | Cytoki Pharma ApS (DK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230381320-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | CYTOKI PHARMA APS (DK) | 2023-11-30 | — | — | US | disclosed |
| US-11806403-B2 | Therapeutic derivatives of interleukin-22 | CYTOKI PHARMA APS (DK) | 2023-11-07 | — | — | US | disclosed |
| EP-4089107-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | CytoKi Pharma ApS (DK) | 2022-11-16 | — | — | EP | disclosed |
| US-20220347304-A1 | Therapeutic Derivatives of Interleukin-22 | CYTOKI PHARMA APS (DK) | 2022-11-03 | — | — | US | disclosed |
| CN-114761422-A | Therapeutic derivatives of interleukin-22 | 赛托奇制药私人有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3819307-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | CytoKi Pharma ApS (DK) | 2021-05-12 | — | — | EP | disclosed |
| EP-3236991-B1 | FGF21 DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447211-B2 | Therapeutic derivatives of interleukin-22 | IL2, IL2RA, IL23R | LMNA 4203/4885SMN1; SMN2 3121/4885GLP1R 667/4885 |
| US-20240252649-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | IL2, IL2RA, IL23R | LMNA 4203/4885SMN1; SMN2 3121/4885GLP1R 667/4885 |
| US-20240108731-A1 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | IL2, IL2RA, IL23R | LMNA 4203/4885SMN1; SMN2 3121/4885GLP1R 667/4885 |
| US-12226487-B2 | Therapeutic derivatives of interleukin-22 | IL2, IL2RA, IL23R | LMNA 4203/4885SMN1; SMN2 3121/4885GLP1R 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.